Genmab A/S

AI Score

0

Unlock

212.50
0.50 (0.24%)
At close: Jan 14, 2025, 5:16 PM
undefined%
Bid n/a
Market Cap 13.50B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 4.859
PE Ratio (ttm) 43.73
Forward PE n/a
Analyst n/a
Ask n/a
Volume 19
Avg. Volume (20D) 70
Open 215.00
Previous Close 212.00
Day's Range 212.50 - 215.00
52-Week Range 188.00 - 289.10
Beta undefined

About GE9.F

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosi...

Industry n/a
Sector n/a
IPO Date Oct 23, 2000
Employees 2,635
Stock Exchange XETRA
Ticker Symbol GE9.F
No News article available yet